M
M

Dividends • Merus

MRUS

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

See below the complete and updated table with all dividends paid and declared history, etc

Excluding Date
Payment
Value ($)
Frequency
2/29/2024
3/22/2024
0,1
Quarterly
11/30/2023
12/22/2023
0,08
Quarterly
8/31/2023
9/22/2023
0,08
Quarterly
8/18/2023
9/5/2023
0,09
Quarterly
5/22/2023
6/6/2023
0,09
Quarterly
5/19/2023
6/12/2023
0,063
Quarterly
3/6/2023
-
0,09
Quarterly